Agreed. They've already dumped in a ton of money into this company over the years. The split allowed them to far more than "double down" here. Super low float and they currently own 40% of the OS in their "funds" but who knows if individual employees own more shares too. There's some strong hands here.
With ~12M OS. $1 / share is a $12M company. Pink sheets do that on air alone. With development stage cancer therapeutics, a lot of patents pending, and distro partners, don't be surprised if this runs into the dollars over the coming weeks and months. Volume proceeds price action. There was heavy short interest / volume recently too. I have the feeling shabby is shorting or other big holders to scoop up even more shares and lock up the float.
News will drive this to massive levels. Shabby want's 100X+ on their investment. Not pennies per share. Dollars. I'd put this in range of $5 - $10+ per share. $10 / share would be a $120M market cap for a cancer biotech with patents and distro partners. Already $100 million invested in this business. $20 per share would be a target for investors to bank ROI on based on what has been put in so far.
Investors want big returns. Plus, it's biotech M&A season too. Keep an eye on this one or buy more shares. I am.
Market Data 
Markets 
AI
